Abbott, St. Jude Medical re-up 'cardiovascular alliance' | Wall Street Beat

April 23, 2012 by MassDevice staff

Abbott and St. Jude Medical re-up and expand their partnership to co-market coronary stents and cardiology devices; also, Thoratec, HeartWare to split the LVAD market?; Arrhythmia Research releases Q1 prelims; ETView Medical inks Taiwan distribution deal; DeHaier Medical in Chinese distribution deal with Timesco; Nephros licences filtration tech from Medica; Toshiba's Vital Images inks MR deal with Olea; and SurgLine launches subsidiary to partner with spine surgeons; plus, a Funding Roundup and analysts' ups and downs. Wall Street Beat

Abbott (NYSE:ABT) and St. Jude Medical (NYSE:STJ) are renewing and expanding an alliance to co-market their cardiovascular products, including Abbott's market-leading Xience coronary stent line.

The deal, which extends a pact the companies inked in 2008, also includes St. Jude's line of cardiac rhythm management, electrophysiology and cardiology products.

Sign up to get our free newsletters delivered straight to your inbox

It will see Abbott and St. Jude jointly promote the other's product offerings to U.S. hospital customers, according to a press release, and includes a separate agreement giving Abbott U.S. distribution rights for St. Jude's hybrid Ilumien FFR/OCT platform and its RadiAnalyzer Xpress system.